Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.50
Dollar change
+1.03
Percentage change
29.68
%
Index- P/E- EPS (ttm)-0.45 Insider Own7.60% Shs Outstand13.01M Perf Week17.19%
Market Cap58.55M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.02M Perf Month-40.55%
Income-5.87M PEG- EPS next Q- Inst Own0.13% Short Float0.04% Perf Quarter-68.97%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio1.78 Perf Half Y-79.55%
Book/sh0.92 P/B4.87 EPS next Y- ROA-38.32% Short Interest0.01M Perf Year-86.76%
Cash/sh0.89 P/C5.06 EPS next 5Y- ROE-40.36% 52W Range3.16 - 31.30 Perf YTD-57.14%
Dividend Est.- P/FCF- EPS past 5Y-95.48% ROI-48.70% 52W High-85.62% Beta-0.38
Dividend TTM- Quick Ratio19.15 Sales past 5Y0.00% Gross Margin- 52W Low42.41% ATR (14)0.70
Dividend Ex-Date- Current Ratio19.15 EPS Y/Y TTM22.82% Oper. Margin0.00% RSI (14)39.87 Volatility15.20% 10.18%
Employees12 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q32.80% Payout- Rel Volume19.54 Prev Close3.47
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume2.86K Price4.50
SMA20-11.46% SMA50-38.46% SMA200-74.37% Trades Volume55,878 Change29.68%
Nov-15-23 04:31PM
Jul-31-23 08:15AM
Apr-03-23 07:25AM
Feb-21-23 06:36AM
Nov-21-22 06:49AM
07:55AM Loading…
Nov-15-22 07:55AM
Oct-25-22 06:55AM
Sep-14-22 06:55AM
Sep-12-22 09:15AM
Jun-20-22 05:27AM
May-24-22 05:46AM
May-18-22 08:05AM
06:14AM
May-16-22 08:56AM
Apr-14-22 10:03AM
06:09AM Loading…
Apr-07-22 06:09AM
Mar-01-22 08:30AM
Feb-17-22 11:40AM
Feb-16-22 08:42PM
Dec-13-21 08:35AM
Nov-22-21 08:15AM
08:00AM
Nov-02-21 04:00AM
Oct-19-21 11:44AM
Sep-10-21 06:18AM
02:42AM
Sep-02-21 08:00AM
Aug-20-21 08:00AM
Aug-05-21 08:00AM
Jul-20-21 04:05PM
11:43AM Loading…
Jul-16-21 11:43AM
Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.